Fulgent Genetics Is Fundamentally Sound

Fulgent’s growth is going to come down this year, according to guidance which was issued just before the coronavirus hit the US in earnest.
From competitors with more recent updates, the picture doesn’t seem to be too alarming, at least not yet.
Fulgent remains a solid growth company, and investors can nibble at the shares on one of the downswings.
The big unknown is of course by how much the coronavirus pandemic will reduce growth, as that situation can get worse.

shareholdersunite.com